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RESEARCH ARTICLE Open Access
Co-occurrence across time and space of
drug- and cannabinoid- exposure and
adverse mental health outcomes in the
National Survey of Drug Use and Health:
combined geotemporospatial and causal
inference analysis
Albert Stuart Reece1,2* and Gary Kenneth Hulse1,2
Abstract: Background: Whilst many studies have linked increased drug and cannabis exposure to adverse mental
health (MH) outcomes their effects on whole populations and geotemporospatial relationships are not well
understood.
Methods: Ecological cohort study of National Survey of Drug Use and Health (NSDUH) geographically-linked
substate-shapefiles 2010–2012 and 2014–2016 supplemented by five-year US American Community Survey. Drugs:
cigarettes, alcohol abuse, last-month cannabis use and last-year cocaine use. MH: any mental illness, major
depressive illness, serious mental illness and suicidal thinking. Data analysis: two-stage, geotemporospatial, robust
generalized linear regression and causal inference methods in R.
Results: 410,138 NSDUH respondents. Average response rate 76.7%. When drug and sociodemographic variables were
combined in geospatial models significant terms including tobacco, alcohol, cannabis exposure and various ethnicities
remained in final models for all four major mental health outcomes. Interactive terms including cannabis were related to any
mental illness (β-estimate = 1.97 (95%C.I. 1.56–2.37), P< 2.2 × 10− 16), major depressive episode (β-estimate = 2.03 (1.54–2.52),
P= 3.6 × 10− 16), serious mental illness (SMI, β-estimate = 2.04 (1.48–2.60), P= 1.0 × 10− 12), suicidal ideation (β-estimate = 1.99
(1.52–2.47), P< 2.2 × 10− 16) and in each case cannabis alone was significantly associated (from β-estimate =− 3.43 (− 4.46 −
−2.42), P= 3.4 × 10− 11) with adverse MH outcomes on complex interactive regression surfaces. Geospatial modelling
showed a monotonic upward trajectory of SMI which doubled (3.62 to 7.06%) as cannabis use increased. Extrapolated to
whole populations cannabis decriminalization (4.26%, (4.18, 4.34%)), Prevalence Ratio (PR) = 1.035(1.034–1.036), attributable
fraction in the exposed (AFE) = 3.28%(3.18–3.37%), P< 10− 300) and legalization (4.75% (4.65, 4.84%), PR = 1.155 (1.153–1.158),
AFE = 12.91% (12.72–13.10%), P < 10− 300) were associated with increased SMI vs. illegal status (4.26, (4.18–4.33%)).
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Conclusions: Data show all four indices of mental ill-health track cannabis exposure across space and time and are robust
to multivariable adjustment for ethnicity, socioeconomics and other drug use. MH deteriorated with cannabis legalization.
Cannabis use-MH data are consistent with causal relationships in the forward direction and include dose-response and
temporal-sequential relationships. Together with similar international reports and numerous mechanistic studies preventative
action to reduce cannabis use is indicated.
Keywords: Cannabis, Cannabinoid, Δ9-tetrahydrocannabinol, Cannabigerol, Mental illness, Major depressive illness, Suicidal
ideation, Pathways and mechanisms
Background
It is widely understood that the use of addictive sub-
stances impacts mental health adversely. Cannabis use
has been linked with numerous adverse mental health
outcomes including reduced educational achievement
[1, 2], increased criminal involvement [3], reduced ac-
complishment of adult goals (education, employment,
stable long term relationships) [4], depression [5–7]
bipolar disorder [8–10], anxiety [7, 11–13], suicidality
[7, 10, 14, 15], schizophrenia, psychosis [16–23] and
other drug use [24].
Indeed one notes that the existence and mission of the
US Substance Abuse and Mental Health Services Ad-
ministration (SAMHSA) aims to minimize the incidence
of both substance abuse and mental ill-health in order to
advance the behavioural health of the nation [25] and
that of the National Institute of Drug Abuse is not dis-
similar [26]. As such it is widely perceived that substance
use may negatively impact major mental health out-
comes. This issue was clearly crystallized by the Director
of the SAMHSA, Dr. Elinore McCantz-Katz in her pres-
entation of the 2017 National Survey of Drug Use and
Health (NSDUH) results which showed in a nationally
representative sample of 18–25 year old young adults
from 2008 to 2017, a doubling of serious mental health
issues from 3.8 to 7.5% and of suicidal plans from 2.0 to
3.7% in the context of past month cannabis use rates ris-
ing from 17.3 to 22.1% but falling use of tobacco and al-
cohol products and low use rates of opioids and cocaine
use [27].
This implies that the unbridled adoption of the wide-
spread use of new addictive psychoactive substances
may potentially have far-reaching psychological implica-
tions with possible impacts at the public health level. It
would appear inevitable that in view of the known ad-
verse effects of cannabis on mental health at the molecu-
lar, cellular and epidemiological levels [28–33] its
widespread deployment in the community would neces-
sarily be causally linked with numerous indices of deteri-
orating mental health. This was of particular concern in
USA in view of the appalling deterioration in the mental
health of young adults described in detail by SAMHSA
(above paragraph).
In the present context this applies particularly to can-
nabis use which, since the takeover of various cannabis
operations by major tobacco corporations, seems poised
at the threshold of major commercialization and global
launch by utilizing the global reach and marketing plat-
form of what is popularly known as the “Big Tobacco”
industry. Notwithstanding its representation in popular
culture as a relatively harmless “soft” drug, cannabis use
has been shown to be linked with a variety of negative
mental health outcomes including cannabis dependency
and use disorder, an impaired lifetime trajectory and ful-
filment of adult goals, an amotivational state, an in-
creased incidence of graduation to use of other addictive
agents, depression, anxiety, bipolar disorder, schizophre-
nia and suicide [2, 4, 17, 24, 28, 34–40].
Such being the case one would expect patterns of
mental health to follow cannabis use across both time
and space. The NSDUH conducted annually by SAMH
SA is a globally unique drug dependency and mental
health research resource which allows investigation of
both substance use and mental health at relatively high
spatial and temporal resolution. Its availability publicly
together with the presence of high definition substate
shapefiles which link these parameters geospatially at de-
fined time points, and which can be matched with other
datasets such as those available through the US census,
presents a globally unique opportunity to conduct an
important public health investigation of these potentially
related trends.
The hypothesis driving the present ecological epi-
demiological investigation was firstly, that substance use
and mental health are linked in a formally demonstrable
manner, and secondly, that increasing rates of cannabis
use would be reflected at the level of population health
trends in a robust manner which persisted after adjust-
ment for other common sociodemographic variables.
These hypotheses was formulated prior to study com-
mencement. We considered that it was important to use
modern geospatiotemporal regression and the tools of
formal causal inference in investigating these questions
and associations, and in particular in assessing the po-
tentially causal nature of the relationship. A corollary of
this is that one might expect metrics of mental health to
Reece and Hulse BMC Public Health         (2020) 20:1655 Page 2 of 15
be worse in states where cannabis is legal. This hypoth-
esis was also tested.
Whilst a link between substance use and adverse men-
tal health is well described in various clinical contexts
what is not clear is the extent to which the mental
health of whole populations is impacted with particular
reference to trends across both space and time and con-
siderations of a putatively causal relationship. It was
these gaps that the present research aimed to fill.
It follows that such an enquiry is particularly timely at
the present juncture given what appears to be a clear
and present international threat to global mental health.
On the international scene cannabis is clearly enjoying a
modern renaissance under its falsely reassuring image as
a low toxicity compound. If concerning trends can be
identified and described in USA then it follows that such
concerns are likely to apply elsewhere, most particularly
if the causal nature of the relationship could be demon-
strated at the population health level. For these reasons
the present study was timely and important not only for




NSDUH Data on drug use by area was downloaded from
the publicly available NSDUH SAMHSA substate shape-
files for 2010–2012 and 2014–2016 [41, 42]. A NSDUH
shapefile for 2012–2014 exists but as it substantially
overlaps the other two its inclusion would significantly
complicate the analysis so this has not been used. This
implies that data for 2015 was not used in the present
analysis. On occasion the triennia were referred to by
their middle year, hence 2011 and 2015. Over 405,000
participants were surveyed across the 6 years. The
2014–2016 shapefile divides the USA into 395 substate
areas based either on county or congressional district
boundaries. The four drugs of interest were last month
cigarette use, past year alcohol abuse or dependence, last
month cannabis use, and last year cocaine use which are
abbreviated to cigmon, abodalc, mrjmon and cocyr in
the NSDUH documentation. These drugs were treated
as covariates for cannabis use. Unfortunately no consist-
ent nomenclature for opioid exposure could be identi-
fied across both shapefiles. The four mental illnesses
mentioned in the NSDUH shapefiles are any mental ill-
ness in the past year, major depressive episode, serious
mental illness in the past year and suicidal thinking
whose NSDUH abbreviations are amiyr, mde, smiyr and
suithyr. Serious mental illness is defined as a “mental,
behavioural or emotional disorder resulting in severe
functional impairment which substantially interferes
with one or more major life activities” and includes the
diagnoses of major depression, bipolar affective disorder
and schizophrenia [43].US Census Bureau County data
on ethnicity and median household income (MHY) was
downloaded from the via the tidycensus package in R
using shapefiles from the R package tigris. Sociodemo-
graphic data was derived from the 5 year American
Community Survey (ACS, “acs5”) conducted by US Cen-
sus. The two NSDUH shapefiles were centred on 2011
and 2015 so they were matched to the ACS 2009–2013
and ACS 2013–2017 respectively. Each respective ACS
shapefile was then interpolated into the substate area
definitions provided by SAMHSA. The two combined
NSDUH shapefiles were then combined together with
the 2014–2016 NSDUH shapefile as the standard (or
“target”) file. Data for Alaska and Hawaii was treated
separately and then added in to the final shapefile and
elided (moved) into their appropriate positions for illus-
tration purposes.
Data on the concentration of cannabinoids in federal
seizures of cannabis to 2011 has been published [44, 45].
In 2011 the concentration of tetrahydrocannabinol
(THC) was 11% and it has been increasing by about 1%
annually. Projected forwards this provides an estimate of
15% in 2015.
Statistics
The analysis was conducted in January 2020. Data was
processed in “R” from CRAN using several packages in-
cluding tidyverse, tidycensus, tigris, sp., sf, spdep and
splm. Graphs and maps were drawn in ggplot2. Hawaii
and Alaska were elided for illustration in sp. (spatial
modelling), converted back to sf (simple features) and
rendered in the USA contiguous Albers Equal Area Con-
ical projection EPSG:102003 as in the R package alber-
susa. Disparate geographical boundaries were conformed
using R::areal. Statistical model reduction from first to
final models was by the classical technique of sequential
elimination of the least significant term until only sig-
nificant terms remain.
The formal analysis of spatially distributed data is not
methodologically trivial but requires dedicated methods
in order to account for the spatial relationships by which
many variables interact and are dependent on each
other. In 1970 Waldo Tobler described the first law of
geography when he noted that things nearby interact
more than things far away [46]. It is important to take
this spatial autocorrelation into account when analyzing
spatially distributed variables. The package splm in the
“R” computing environment is purpose built for such ap-
plications. In particular it includes the spatial panel gen-
eralized method of moments (spgm) function which is
ideally suited to short panel datasets such as this one
and the spatial panel random error maximum likelihood
(spreml) function which includes sophisticated methods
to account for various spatial lag and error structures.
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Both techniques allow the use of instrumental variables.
Thus both techniques have been applied to this dataset.
Geospatiotemporal data processing was done using the
“R” package splm (spatial panel linear modelling) with
the spatial panel generalized method of moments (spgm)
function as it is ideally suited to short panel data such as
this and also with the recent spml refinement spreml
(spatial panel random error maximum likelihood) func-
tion which incorporates sophisticated modelling of error
and autocorrelation structures. The standard spgm
model was spatially lagged, used the full weights method,
a generalized two-step least squared estimation method,
spatial error and lagged the instrumental variables. In-
strumental variables were the local cannabis ethnic po-
tency index (LCEPI) defined below. For spreml models
the full model was used including spatial lagging, spatial
errors of Kapoor, Kelejian and Prucha [47], autocorrel-
ation order 1 errors and the same ethnic instrumental
variables as above. Spatial errors and spatial weights
were calculated using the spdep::poly2nb function and
these data were updated to include conceptual links
from the Hawaiian islands to south-eastern California
and from Alaska to Washington state and Oregon.
Modelling of fitted values was done by matrix multipli-
cation of mean, minimum and maximum values into
model coefficients as indicated. Analysis of the impact of
cannabis legal status at state level was undertaken from
the state-based NSDUH data table (“state_saes_final.-
sas7bdat”) supplemented by cannabis legal status defined
from an internet search. Data was manipulated with
dplyr and the resulting two-by-two tables were analyzed
in epiR.
Causal inference analysis
Inverse probability weighting was conducted for the
whole sample using the R package ipw. This transforms
our study from merely ecological and observational to a
pseudo-randomized design where causal inferential rela-
tionships can properly be assigned. These weights were
then entered into robust generalized linear regression
using the R package survey with substate region as the
identifying variable. In order to calculate a model stand-
ard deviation the weights were also utilized in mixed ef-
fects regression using the R package nlme again with
substate region as the grouping variable.
The e-Value is a new index which was recently defined
[48] which quantitates the degree of association with
both the exposure and the outcome which would be re-
quired of an unmeasured confounding variable to ex-
plain away the observed significant finding [48–53]. It is
presented on the risk ratio scale. Research literature
commonly contains e-Values of 1.25 and above [52]. e-
Values were computed from relative risks and regression
coefficients using the R package EValue. P < 0.05 was
considered significant throughout.
Data availability statement
Data including shapefiles and R programming script is
made publicly available on the Mendeley Data Archive
at this URL:
https://doi.org/10.17632/gyckst6rx8.1. The original





Ethical approval for this study was provided by the Uni-
versity of Western Australia Human Research Ethics
Committee 08/01/2020 (No. RA/4/20/4724).
Results
Of 534,000 individuals approached 410,138 responded to
the six NSDUH surveys, a completion rate of 76.7%.
Data for the 2 years 2011 and 2015 are listed as median
and interquartile ranges and compared non-
parametrically in Supplementary Table 1.
Figure 1 shows the rates of mental illness for the four
NSDUH-defined mental health disorders included in the
SAMHSA substate shapefiles of any mental illness,
major depressive episode, serious mental illness and sui-
cidal thinking.
Figure 2 shows map-graphically the distribution of the
use of various drugs across USA in the two NSDUH
triennia.
Figure 3 shows the rates of the four mental illness syn-
dromes by drug use at state level. The slope (as β-
estimates) and significance of these regression lines is
shown in Supplementary Table 2. The slopes for three
of the lines is significant.
Supplementary Fig. 1 shows the ethnic composition of
USA for the two periods.
Supplementary Fig. 2 shows the rate of median house-
hold income in the USA in the two periods 2010–2012
and 2014–2016.
National level NSDUH data make it clear that there
are considerable differences between various ethnicities
in drug use and especially daily / near daily cannabis
use. These can be averaged out by ethnicity to derive a
cannabis use frequency index at the national level. It is
likely that regional data also impacts cannabis use by
ethnic populations so an index of this was derived by
multiplying the local monthly cannabis use by the na-
tional ethnic near daily cannabis use to derive a local
cannabis ethnic daily index (LCEDI) at state level. Since
the THC concentration of cannabis has also been in-
creasing the LCEDI can in turn be multiplied by the
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THC content to produce a local cannabis ethnic daily
potency index (LCEDPI) of local ethnic exposure to can-
nabinoids. This LCEDPI index may also be referred to as
an “Ethnic score” and it has been used as an important
instrumental variable controlling for environmental can-
nabinoid exposure arising from the sociocultural envir-
onment rather than any intrinsic ethnic risk propensity
(such as pharmacogenomic susceptibilities). The various
LCEDI and LCEDPI are listed in Supplementary Table 3
and illustrated in Supplementary Figs. 3 and 4.
Supplementary Fig. 5 shows the relative rise in these in-
dices from the 2010–2012 baseline and the relative rise
comparable to the mean rise by ethnicities.
First degree edge and corner (“queen”) spatial weights
were calculated between substate areas by R::spdsep::
poly2nb and updated for Alaska, Hawaii and Richmond
Island (in New York) as shown in Supplementary Fig. 6A,
with final results as shown in Supplementary Fig. 6B.
Supplementary Table 4 presents the spgm results
when serious mental illness is regressed against each of
drugs, median household income, and ethnicity variables
separately with the ethnic LCEPI included as instrumen-
tal variables. As noted, only the drug related variables
are significant. Terms including cannabis are significant
(from β-estimate = 0.08 (95%C.I. 0.02–0.13), P = 0.009).
Supplementary Table 5 performs the same task for ser-
ious mental illness using spreml regression. The signifi-
cance level of all terms is increased. Both income and
racial composition now become significant. Terms in-
cluding cannabis are significant (from β-estimate = 2.34
(1.71–2.97), P = 1.4 × 10− 13).
All the independent variables were then included in a
final spgm model shown in Table 1 for all four mental
illnesses listed by SAMHSA. All four described drugs
survive model reduction and appear in final models. The
table is notable for the high level of significance of many
drugs including terms involving cannabis (from β-
estimate = 1.74, (0.97, 2.51), P = 9.9 × 10− 6). Income and
ethnic factors do not survive model reduction. Hence
final models include drug related factors only.
Table 2 presents results from a similar exercise apply-
ing the advanced techniques of spreml spatial regression.
Again all four drugs are included at high level of signifi-
cance. Terms including cannabis appear (from β-
estimate = 1.84 (0.30, 2.39), P ≤ 3.0 × 10− 11) for all four
illness syndromes. Terms including cannabis appear
(from β-estimate = − 3.31 (2.58, 4.04), P ≤ 2.2 × 10− 16 for
any mental illness and (from β-estimate = 2.13 (1.63,
Fig. 1 Mental Illness across USA by substate area. Data from NSDUH Shapefiles
Fig. 2 Drug Use across USA by substate area. Data from NSDUH Shapefiles
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2.62), P ≤ 2.2 × 10− 16) for major depressive episode. Eth-
nic factors appear in all models. Median household in-
come only appears in the model for serious mental
illness.
As mentioned spreml models give advanced access to
the error structure of spatial models. It is therefore
mandatory to give careful attention to correct model
specification. Supplementary Table 6 shows a selection
of the principal error structures and their various specifi-
cations. The log maximal likelihood of the models is
listed at model optimization, together with the value of
the spatial Hausman test comparing each model to the
full model. In each case high levels of statistical signifi-
cance are demonstrated with all P < 2.2 × 10− 16. These
results confirm that the model specification which was
presented above, namely the full sem2srre + lag model, is
technically correct.
The rates of mental illness can be aggregated into state
areas to compare mental illness rates by the legal status
of cannabis.
The final spreml model for serious mental illness may
be used to compute fitted values. When mean values for
tobacco and alcohol abuse together with minimum or
maximum values for monthly cannabis use are entered
into this model minimum and maximum values for ser-
ious mental illness of 3.62 and 7.06% result (maximum =
1.95-fold minimum value). Figure 4a shows the modelled
rate of serious mental illness as a function of cannabis
use decile (Supplementary Table 7).
Data also lend themselves to analysis by the formal tech-
niques of causal inference. Inverse probability weights
were calculated as described and entered into robust gen-
eralized linear regression equations. The effect of conduct-
ing regression procedures with inverse probability weights
is to make the sample pseudo-randomly conducted with
regard to the exposure of interest, in this case cannabis
use, so that the outcome can be properly assessed without
the confounding arising from the exposure being non-
randomly distributed across the other covariate exposure
groups. The results of final models from additive and
interactive models as shown in Table 3. In this Table the
dependent variable is serious mental illness rates and the
list of covariates includes five racial groups, median house-
hold income, ethnic cannabis use scores (LCEDI) and
Fig. 3 Mental Illness by Substance Exposure. Data from NSDUH Shapefiles
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Table 1 Spatial panel general method of moments regression – final models
General Parameters Model
Instrumental Variables Parameter Estimate (95%C.I.) P-Value Para-meters Value P-Value
Any Mental Illness
NHWhite_Score spgm (amiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHBlack_Score Cigarettes: Cannabis: Alcohol_Abuse −0.05 (− 0.07--0.03) 2.5E-05 rho − 0.5152 N/A
Hispanic_Score Cigarettes: Alcohol_Abuse 0.11 (0.06–0.16) 4.6E-05 sigma^2_ 0.003 N/A
NHAsian_Score Cannabis: Alcohol_Abuse 1.21 (0.61–1.81) 7.9E-05 lambda 0.6753 1.30E-05
NHAIAN_Score Cigarettes: Cannabis 0.09 (0.05–0.13) 0.0001
Alcohol_Abuse −2.43 (−3.72--1.14) 0.0002
Cigarettes −0.17 (− 0.26--0.08) 0.0003
Cannabis −1.99 (−3.08--0.9) 0.0004
Cocaine 0.05 (0.01–0.09) 0.0128
Median_Household_Income −0.03 (− 0.06–0) 0.0339
Afr.Am_Pop_Fraction 0.03 (0–0.06) 0.0485
Major Depressive Episode
NHWhite_Score spgm (mde ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHBlack_Score Cannabis: Alcohol_Abuse 1.74 (0.97–2.51) 9.9E-06 rho −0.6813 N/A
Hispanic_Score Cigarettes: Cannabis: Alcohol_Abuse −0.07 (− 0.1--0.04) 2.6E-05 sigma^2 0.005 N/A
NHAsian_Score Cannabis −2.98 (− 4.38--1.58) 2.9E-05 lambda 0.8945 1.20E-04
NHAIAN_Score Alcohol_Abuse −3.46 (−5.1--1.82) 3.8E-05
Cigarettes: Cannabis 0.12 (0.06–0.18) 6.3E-05
Cigarettes: Alcohol_Abuse 0.13 (0.06–0.2) 8.1E-05
Cigarettes −0.23 (− 0.35--0.11) 2.4E-04
Serious Mental Illness
NHWhite_Score spgm (smiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHBlack_Score Cigarettes: Alcohol_Abuse 0.1 (0.03–0.17) 0.0048 rho − 0.7386 N/A
Hispanic_Score Cigarettes −0.17 (− 0.29--0.05) 0.0058 sigma^2 0.0055 N/A
NHAsian_Score Cigarettes: Cannabis: Alcohol_Abuse −0.04 (− 0.07--0.01) 0.0082 lambda 0.7722 3.37E-07
NHAIAN_Score Cocaine 0.07 (0.02–0.12) 0.0087
Cigarettes: Cannabis 0.08 (0.02–0.14) 0.0092
Alcohol_Abuse −2.14 (−3.82--0.46) 0.0126
Cannabis: Alcohol_Abuse 0.96 (0.17–1.75) 0.0169
Cannabis −1.66 (−3.09--0.23) 0.0231
NHWhite_Score Suicidal Thoughts Past Year
NHBlack_Score spgm (suithyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
Hispanic_Score Alcohol_Abuse −3.05 (− 4.67--1.43) 0.0002 rho −0.6752 N/A
NHAsian_Score Cannabis: Alcohol_Abuse 1.37 (0.61–2.13) 0.0004 sigma^2_ 0.0051 N/A
NHAIAN_Score Cigarettes: Alcohol_Abuse 0.12 (0.06–0.18) 0.0004 lambda 0.7757 7.96E-12
Cigarettes: Cannabis: Alcohol_Abuse −0.05 (− 0.08--0.02) 0.0012
Cigarettes −0.19 (− 0.31--0.07) 0.0016
Cannabis −2.18 (−3.55--0.81) 0.0019
Cigarettes: Cannabis 0.08 (0.02–0.14) 0.0037
Abbreviations
5_Races: Caucasian-American, African-American, Hispanic-American, Asian-American, NHAIAN
Technical Notes:
phi:- Idiosyncratic component of the spatial error term
psi:- Individual time-invariant component of the spatial error term
rho:- Spatial autoregressive parameter
lambda:- Spatial autocorrelation coefficient
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drug use variables for cigarettes, binge alcohol, monthly
cannabis and annual cocaine. In additive models both can-
nabis use (β-estimate = − 0.43 (− 0.65 - -0.21), P = 0.0002),
and Caucasian American cannabis use (β-estimate = 0.95
(0.05–1.85), P = 0.0396) survived model reduction and
were significant. In models including a four-way cigarette:
alcohol:cannabis:cocaine interaction, terms including can-
nabis were significant from (β-estimate = 0.12 (0.10, 0.14),
P < 10− 16).
In inverse probability weighted mixed effects additive
and interactive models with the same list of dependent
variables and predictive covariates, terms including can-
nabis were again significant (from β-estimate = 0.11
(0.07, 1.15), 1.5 × 10− 5; Supplementary Table 8).
Sensitivity analyses may be conducted on these odds
ratio, mixed effects and geospatial data with many highly
significant e-Value results as shown in Supplementary
Table 9. The minimal e-values in the geotemporospatial
analyses ranged from 3.13 to 2,660,000 (Supplementary
Table 9). This compares positively to comments in the
literature that e-Values above 1.25 are often quoted in
scientific reports [52]. Such elevated values make uncon-
trolled confounding extremely unlikely and point to a
relationship which is truly causal in nature.
When one considers state-based data for the 6 years
of the NSUDH shapefiles states with legal cannabis
status had an increased rate of serious mental illness
(Prevalence ratio (PR) = 1.09 (95%C.I. 1.04, 1.13), at-
tributable fraction in the exposed (AFE) = 7.93% (4.17,
11.55%), attributable fraction in the population
(AFP) = 0.70% (0.035, 1.06%), Chi.Squ. = 16.25, df = 1,
P = 5.55 × 10− 5).
Figure 4b and Table 4 show the mean rate of serious
mental illness as a function of cannabis legal status when
NSDUH results are extrapolated onto whole state popu-
lations. The values for the Illegal, Medical, Decrimina-
lized and Legal Status are 4.26 (4.18, 4.34%), 4.11 (4.01,
4.21%), 4.01 (3.83, 4.19%) and 4.75 (4.65, 4.85%) respect-
ively. The notches for the Decriminalized and Legal sta-
tuses are noted to not overlap those of the illegal status.
Cannabis decriminalization was associated with an in-
creased incidence of serious mental illness (PR = 1.035
(1.034, 1.036), AFP = 3.28% (3.18, 3.37%), AFE = 1.13%
(1.09, 1.16%), ChiSq. = 4635.1, df = 1, P < < 10− 300), as
was cannabis legalization (PR = 1.155 (1.153, 1.158),
AFE = 12.91% (12.72, 13.10%), AFP = 0.83% (0.82, 0.85%),
ChiSq. = 15,015.1, df = 1, P < < 10− 300).
Supplementary Fig. 7 shows the rate of all mental ill-
ness syndromes against cannabis legalization status from
state based data. The Chi-squared comparisons are
shown in Supplementary Table 10. Results for any men-
tal illness and suicidal ideation are both significant (P =
0.0395 and P = 0.0395) are that for serious mental illness
approaches significance (P = 0.0654).
Discussion
Main findings
This study applies current geospatial techniques to the
analysis of the four metrics of mental illness spatially de-
scribed by SAMHSA in recent iterations of NSDUH.
Using spatial panel generalized method of moments
(spgm) techniques drug-related variables pertaining to
tobacco, alcohol, abuse cannabis and cocaine were found
to be more significant than socioeconomic and ethno-
graphic factors after correction using estimates for in-
creased local exposure to cannabis in some ethnic
groups. For cannabis this included terms significant
from P < 10− 5. When more advanced spatial techniques
such as the full spatial panel random error maximum
likelihood (spreml) models were used these results were
confirmed overall and included an increased level of
statistical significance for terms including cannabis for
all four mental illness metrics from P < 4.0 × 10− 11.
Therefore geospatial techniques increased the precision
of the parameter estimates by several orders of
magnitude.
It is of interest to consider these findings in the light
of the remarks mentioned in the Introductory section re-
lating to the poor and declining mental health of US
young adults. First, there is a very obvious association
nationally with the dramatic decline in the mental health
of young adults in the USA and rising levels of cannabis
use in that age demographic [27, 54]. Our results con-
firm this trend at the higher geospatial resolution of the
substate level.
Secondly both study hypotheses are confirmed by
study results. All indices of mental health (any mental
illness, major depressive illness, serious mental illness
and suicidal ideation) are robustly associated with the
use of all addictive substances investigated. It is equally
clear that the hypothesized relationships between canna-
bis and all four indices of mental ill-health are not only
established, but robust to multivariable adjustment.
Moreover analysis of the data with inverse probability
weights in both mixed effects models and robust gener-
alized linear models together with sensitivity analyses in-
dicated that the relationship fulfilled the criteria of
causality in each case.
Any mental health issues and suicidal ideation were
also shown to be worse in parallel with liberalized can-
nabis policies. The result for serious mental illness
approached significance (P = 0.06).
Pathways and mechanisms
Since the existence of plausible biological pathways
explaining a potential causal pathway from cannabis ex-
posure to mental illness is a foundational pillar of causal
algorithms such as that of Hill [55] it becomes very im-
portant to consider briefly some of the neurotoxic
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Table 2 Spatial panel random error maximum likelihood regression – final models
General Parameters Model
Instrumental Variables Parameter Estimate (95%C.I.) P-Value Para-meters Value P-Value
Any Mental Illness
spreml (amiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score Alcohol_Abuse −4.19 (− 5.02--3.36) < 2.2e-16 phi 0.008 0.9908
NHBlack_Score Cannabis: Alcohol_Abuse 1.96 (1.55–2.37) < 2.2e-16 psi 0.4002 0.251
Hispanic_Score Cannabis −3.33 (−4.06--2.6) < 2.2e-16 rho −0.1507 0.3296
NHAsian_Score Cigarettes: Alcohol_Abuse 0.15 (0.11–0.19) < 2.2e-16 lambda 0.2336 0.0425
NHAIAN_Score Cigarettes −0.26 (−0.32--0.2) 4.00E-15
Cigarettes: Cannabis: Alcohol_Abuse −0.07 (− 0.09--0.05) 2.70E-15
Cigarettes: Cannabis 0.12 (0.09–0.15) 1.20E-13
Caucasian-Amer.Pop_Fraction 0.09 (0.06–0.12) 1.00E-10
Median_Household_Income −0.09 (− 0.12--0.06) 1.30E-06
Hispanic_Pop_Fraction −0.01 (− 0.02–0) 0.0033
African-Amer._Pop_Fraction −0.01 (− 0.02–0) 0.0062
Asian_Pop_Fraction 0.02 (0.01–0.03) 0.0131
Major Depressive Episode
spreml (mde ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine +Med_HH_Income + 5_Races)
NHWhite_Score Cannabis: Alcohol_Abuse 2.03 (1.54–2.52) 3.60E-16 phi 0.1573 0.9579
NHBlack_Score Alcohol_Abuse −4.14 (−5.14--3.14) 4.90E-16 psi 0.3124 0.8569
Hispanic_Score Cannabis −3.53 (− 4.41--2.65) 3.80E-15 rho −0.3358 0.0325
NHAsian_Score Cigarettes: Alcohol_Abuse 0.16 (0.12–0.2) 1.60E-12 lambda 0.3809 0.0002
NHAIAN_Score Cigarettes: Cannabis: Alcohol_Abuse −0.08 (−0.1--0.06) 1.90E-12
Cigarettes −0.27 (− 0.35--0.19) 4.50E-12
Cigarettes: Cannabis 0.14 (0.1–0.18) 5.70E-12
Caucasian-Amer._Pop_Fraction 0.08 (0.05–0.11) 2.20E-08
Hispanic_Pop_Fraction −0.02 (−0.03−−0.01) 0.0003
African-Amer._Pop_Fraction −0.01 (− 0.02–0) 0.0025
AIAN_Pop_Fraction -0.01 (−0.02–0) 0.0085
Median Household Income −0.04 (− 0.07--0.01) 0.0312
Serious Mental Illness
spreml (smiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score Caucasian-Amer. 0.21 (0.17–0.25) < 2.2e-16 phi 0.176 NA
NHBlack_Score Median Household Income −0.22 (−0.27--0.17) < 2.2e-16 psi 0.153 NA
Hispanic_Score Alcohol_Abuse −4.55 (−5.69--3.41) 6.20E-15 rho 0.1311 0.2141
NHAsian_Score Cannabis: Alcohol_Abuse 2.04 (1.48–2.6) 1.00E-12 lambda 0.0618 0.4449
NHAIAN_Score Cannabis −3.44 (−4.46--2.42) 3.40E-11
Cigarettes:Alcohol_Abuse 0.17 (0.12–0.22) 7.60E-11
Cigarettes −0.27 (−0.36--0.18) 1.50E-09
Cigarettes: Cannabis: Alcohol_Abuse −0.08 (− 0.11--0.05) 2.90E-09
Cigarettes: Cannabis 0.13 (0.08–0.18) 2.00E-08
African-Amer._Pop_Fraction −0.02 (−0.03--0.01) 9.30E-06
Hispanic_Pop_Fraction −0.02 (− 0.03--0.01) 0.005
Asian_Pop_Fraction 0.02 (0–0.04) 0.0089
Suicidal Thoughts Past Year
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mechanisms which have been described in the published
literature. We note that numerous biological pathways
have been described linking cannabinoid exposure to
neurotoxicity and adverse neuropsychiatric outcomes.
Several genetic and epigenetic pathways have been
described linking altered dopamine receptor gene and
other gene expression with addictive, behavioural and
autistic outcomes [56–60]. Cannabinoids have been
shown to have adverse effects on neural stem cell activ-
ity [61] which negatively and importantly impacts brain
Table 2 Spatial panel random error maximum likelihood regression – final models (Continued)
General Parameters Model
Instrumental Variables Parameter Estimate (95%C.I.) P-Value Para-meters Value P-Value
spreml (suithyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score Alcohol_Abuse −4.36 (−5.33--3.39) < 2.2e-16 phi 0.0225 0.9737
NHBlack_Score Cannabis: Alcohol_Abuse 1.99 (1.52–2.46) < 2.2e-16 psi 0.1854 0.726
Hispanic_Score Cannabis −3.4 (−4.26--2.54) 1.05E-14 rho −0.1314 0.2451
NHAsian_Score Cigarettes: Alcohol_Abuse 0.16 (0.12–0.2) 6.72E-13 lambda 0.2824 0.0005
NHAIAN_Score Cigarettes −0.26 (− 0.34--0.18) 8.28E-12
Cigarettes: Cannabis: Alcohol_Abuse −0.07 (− 0.09--0.05) 8.14E-11
Cigarettes: Cannabis 0.12 (0.08–0.16) 7.25E-10
Hispanic_Pop_Fraction −0.02 (−0.03--0.01) 5.53E-08
African-Amer._Pop_Fraction −0.02 (− 0.03--0.01) 2.89E-07
Caucasian-Amer._Pop_Fraction 0.07 (0.04–0.1) 1.12E-06
Asian_Pop_Fraction 0.03 (0.02–0.04) 1.03E-05
Median Household Income −0.08 (−0.12--0.04) 5.70E-05
Abbreviations
5_Races: Caucasian-American, African-American, Hispanic-American, Asian-American, NHAIAN
Technical Notes:
phi:- Idiosyncratic component of the spatial error term
psi:- Individual time-invariant component of the spatial error term
rho:- Spatial autoregressive parameter
lambda:- Spatial autocorrelation coefficient
Fig. 4 Modelled Relationships and Legal Status. a Serious Mental illness by Rising Cannabis Concentration. b Serious Mental Illness by
Legal Status
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plasticity and brain aging [62]. Cannabinoids can also in-
duce microglial activation and priming [63] which was
recently shown to set the brain on a pathway which
phenocopies aging [64]. Cannabis exposure has also
been shown to age the human organism in a longitu-
dinal study of cardiovascular ageing [64]. Cannabinoids
have been shown to decouple both synapses, by nega-
tively impacting the neurexin-neuroligin machinery
which scaffolds them [65–68], and grey-white matter
coupling [69]. Similarly cannabinoids negatively impact
both actin and tubulin expression and dynamics [65]
impacting axonal guidance and growth cone mechanics
[70] and chromosomal mechanisms, chromosomal seg-
regation and cell division [71]. Cannabis has a negative
effect on cell growth, macromolecular synthesis and cell
division [72, 73] and adversely affects the slit:robo ratio
which controls the hypertrophic exuberant growth of
the massive human cerebral cortex [74–76].
It is also important to appreciate that such negative
cellular mechanisms have been ascribed to cannabinoids
other than simply Δ9-tetrahydrocannabinol as other
chemical moieties, including cannabidiol, cannabichro-
mene and cannabinol have been similarly implicated
[77–80]. Indeed it is known that cannabis oil is toxic to
many plants including the leaves of Cannabis sativa it-
self [81].
It is also relevant in this regard that both the epigen-
etic actions and chromosomal mis-segregation actions of
cannabinoids imply not only genotoxicity and epigen-
otoxicity in the exposed individuals themselves, but also
heritable changes to several subsequent generations [82].
As the use of cannabis becomes both more widespread
and consumption increases in existing users, cannabin-
oid exposure will likely become multigenerational and
open new routes to cannabinoid-induced heritable neu-
ropsychopathology. This was recently shown for autism
in USA [83, 84].
Whilst this study relates to the mental health of adults
it has been shown that cannabis use is linked with ad-
verse mental health outcomes in offspring of exposed
populations including autism and ADHD-like changes
[83–94]. This important datum further amplifies the sig-
nificance of the present investigation into the cross-
generational context.
Hence taken together these data overall clearly indi-
cate not only that increased cannabis use is causally as-
sociated with adverse mental health outcomes at the
statistical and epidemiological level, but that multiple
biological pathways exist to explain the causal relation-
ship mechanistically. Indeed data in this report indicates
that the cannabis-mental illness relationship fulfills all
ten of Hill’s criteria for causal relationships [55], in
addition to the unequivocal demonstration of very close
relationships across space and time and the results of
the causal inferential techniques employed.
Strengths and limitations
Our study has a number of strengths and limitations. Its
strengths include investigation of what we believe to be
Table 3 Robust Generalized Linear Models Results
Parameter Estimate C.I. P-Value
Additive Models
Cocaine 0.27 (0.13–0.41) 7.6E-05
Alcohol 0.09 (0.05–0.13) 0.0001
Asian.Am 0.12 (0.06–0.18) 0.0005
Median Household Income 0.22 (0.06–0.38) 0.0041
Cauc.Am.Cannabis 0.95 (0.05–1.85) 0.0396
Cannabis −0.43 (−0.65--0.21) 0.0002
Cigarettes −0.02 (−0.04–0.00) 6.2E-05
Afric.Am −0.09 (−0.13--0.05) 5.8E-06
Hispanic −0.22 (−0.32--0.12) 2.4E-06
Interactive Models
Cigarettes: Alcohol 0.06 (0.04–0.08) 3.2E-26
Cigarettes: Cannabis 0.12 (0.10–0.14) 1.5E-21
Asian.Am 0.07 (0.05–0.09) 4.0E-19
Alcohol: Cannabis 0.51 (0.39–0.63) 2.7E-17
Alcohol: Cannabis: Cocaine 0.04 (0.02–0.06) 2.2E-07
Afric.Am.Cannabis −0.19 (−0.27--0.11) 3.8E-05
Alcohol: Cocaine −0.07 (−0.11−− 0.03) 1.9E-05
AIAN.Am -0.03 (−0.03--0.03) 3.7E-07
Cigarettes: Alcohol: Cannabis −0.02 (−0.02--0.02) 2.0E-18
Afric.Am −0.05 (−0.07--0.03) 4.0E-20
Alcohol −1.41 (−1.65--1.17) 2.0E-26
Cigarettes −0.30 (−0.36--0.24) 6.4E-28
Cannabis −2.75 (−3.20--2.30) 3.4E-28









Decriminalized 6,106,622 12,033,634 143,356,702 4.26% (4.18, 4.34%) 8.39%
Illegal 11,650,796 17,995,589 283,172,529 4.11% (4.01, 4.21%) 6.35%
Legal 805,083 2,337,511 16,936,978 4.75% (4.65, 4.85%) 13.80%
Medical 7,394,236 16,516,827 184,526,713 4.01% (3.83, 4.19%) 8.95%
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the best most carefully geospatially and temporally de-
fined dataset in the world which measures both drug use
and mental health outcomes in a synchronized and coor-
dinated manner. Also we believe that the application of
modern advanced geospatial analysis to these public
health problems is also new and novel and innovative.
The limitations of this study relate mainly to its eco-
logical design. For example we had to estimate local use
of cannabis by ethnic origin as substate estimates were
not available. Similarly individual respondent data from
the survey is not available outside of dedicated US re-
search centres and it is clear that access to such data
would increase the power of the present investigation.
We feel therefore that while the present analysis repre-
sents an important contribution to the literature in the
field it also provides a strong impetus for further
research.
Generalizability
Given that NSDUH is conducted carefully in a nationally
representative manner of the non-institutionalized adult
US population the present results are likely to be
generalizable to other developed nations. Moreover as it
appears that the geospatially observed trends are rooted
in the biological processes and mechanisms, what we are
seeing at the public health level reflects downstream
pharmacological effects from altered biological processes
occurring in human neurophysiology. We note that all
five of the major racial groups investigated herein
showed significant statistical relationships with mental
health metrics suggesting cross-racial effects.
Conclusions
Our interpretation of these results is that all four of the
adverse mental health outcomes mapped geotemporos-
patially by SAMHSA are linked upon formal geospatial
analysis with the use of all four of the addictive drugs
for which data was available. On testing of single do-
mains of variables against serious mental illness only the
drug group was significant, whilst median household in-
come and racial profiling were not. After adjustment for
the usual battery of ethnic, drug use and socioeconomic
covariates, terms including cannabis were significantly
linked with all four domains of mental ill-health from a
high level of statistical significance, implying that the
widespread deployment of cannabis and cannabinoids
for primarily commercial motivations is likely to carry
with it major negative mental health implications for the
future. Inverse probability weighting was employed to
transform data from a purely ecological observational
data series to a formal pseudo-randomized design.
Highly significant estimates and confidence intervals at
inverse probability-weighted robust and mixed effects re-
gression together with large e-Values clearly indicate
that these results fulfil the criteria for causal relation-
ships. These epidemiological relationships are consistent
with numerous cellular and molecular mechanisms de-
scribing cannabis-related neurotoxicity.
We find these results to be of great concern not only
for the public health community within the USA but
also for the wider international community.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12889-020-09748-5.
Additional file 1: Supplementary Table 1. Overall Data by Year.
Supplementary Table 2. Line Slopes for Cannabis: Mental Illness
Relationships (Fig. 3). Supplementary Table 3. Ethnic Cannabis
Consumption Indices Supplementary Table 4. Spatial Panel General
Method of Moments Models (Spgm) by Variable Domain.
Supplementary Table 5. Spatial Panel Random Error Maximum
Likelihood Models (Spreml) by Variable Domain. Supplementary
Table 6. Comparison of Spreml Model Error Structure – Log Likelihood
Values. Supplementary Table 7. Deciles of Cannabis Use and Modelled
Serious Mental Illness. Supplementary Table 8. Mixed Effects
Regression Results. Supplementary Table 9. Sensitivity Analysis –
eValues. Supplementary Table 10. Analysis of Chi Squared Table for









Am: -American (Ethnicity); ACS: American Community Survey;
AFE: Attributable Fraction in the Exposed; AFP: Attributable Fraction in the
Population; CRAN: Comprehensive R Archive Network; EPSG: European
Petroleum Survey Group; e-Value: Expected Value; KKP: Kapoor, Kelejian and
Prucha; LCEDI: Local Cannabis Ethnic Daily Index; LCEDPI: Local Cannabis
Ethnic Daily Potency Index; LCEPI: Local Cannabis Ethnic Potency Index;
MH: Mental Health; MHY: Median Household Income; NH-: Non-Hispanic;
NSDUH: National Survey of Drug Use and Health; PR: Prevalence Ratio; SAMH
SA: Substance Abuse and Mental Health Services Administration; SMI: Serious
Mental Illness; spgm: Spatial Panel General Moments; spml: Spatial Panel
Maximum Likelihood; spreml: Spatial Panel Random Effects Maximum




ASR assembled the data, designed and conducted the analyses, and wrote
the first manuscript draft. GKH provided technical and logistic support, co-
wrote the paper, assisted with gaining ethical approval, provided advice on
manuscript preparation and general guidance to study conduct. All authors
have read and approved the manuscript.
Funding
No funding was provided for this study. No funding organization played any
role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or approval of
the manuscript; and decision to submit the manuscript for publication.
Reece and Hulse BMC Public Health         (2020) 20:1655 Page 12 of 15
Availability of data and materials
No permissions are required to access the data which was used and collated
in this study, e.g. NSDUH study. Data including shapefiles and R
programming script is made publicly available on the Mendeley Data
Archive at this URL: https://doi.org/10.17632/gyckst6rx8.1 . The original SAMH
SA shapefiles may be found at https://www.samhsa.gov/data/report/2014-2
016-nsduh-substate-region-shapefile and https://www.samhsa.gov/data/
report/2012-2014-nsduh-substate-region-shapefile.
Ethics approval and consent to participate
The Human Research Ethics Committee of the University of Western
Australia provided ethical approval for the study to be undertaken 7th June
2019 (No. RA/4/20/4724). Ethics approval was not required to access the data
in the first instance. However Ethical approval provided permission to access,




The authors declare that they have no competing interests.
Received: 27 June 2020 Accepted: 21 October 2020
References
1. Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational
achievement. Addiction. 2003;98(12):1681–92.
2. Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton
GC, Silins E, Hutchinson DM. Cannabis use and educational achievement:
findings from three Australasian cohort studies. Drug Alcohol Depend. 2010;
110(3):247–53.
3. Fergusson DM, Swain-Campbell NR, Horwood LJ. Arrests and convictions for
cannabis related offences in a New Zealand birth cohort. Drug Alcohol
Depend. 2003;70(1):53–63.
4. Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction.
2008;103(6):969–76 discussion 977-968.
5. Dierker L, Selya A, Lanza S, Li R, Rose J. Depression and marijuana use
disorder symptoms among current marijuana users. Addict Behav. 2018;76:
161–8.
6. Filbey FM, Aslan S, Lu H, Peng SL. Residual effects of THC via novel
measures of brain perfusion and metabolism in a large Group of Chronic
Cannabis Users. Neuropsychopharmacology. 2018;43(4):700–7.
7. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein
N, Cipriani A, Dendukuri N, et al. Association of Cannabis use in adolescence
and risk of depression, anxiety, and Suicidality in young adulthood: a
systematic review and meta-analysisCannabis use in adolescence and risk of
depression, anxiety, and Suicidality in young AdulthoodCannabis use in
adolescence and risk of depression, anxiety, and Suicidality in young
adulthood. JAMA Psychiatry. 2019;76(4):426–34.
8. Hanna RC, Perez JM, Ghose S. Cannabis and development of dual
diagnoses: a literature review. Am J Drug Alcohol Abuse. 2017;43(4):442–55.
9. Marwaha S, Winsper C, Bebbington P, Smith D. Cannabis use and
hypomania in young people: a prospective analysis. Schizophr Bull. 2018;
44(6):1267–74.
10. Bartoli F, Crocamo C, Carra G. Cannabis use disorder and suicide attempts in
bipolar disorder: a meta-analysis. Neurosci Biobehav Rev. 2019;103:14–20.
11. Otten R, Huizink AC, Monshouwer K, Creemers HE, Onrust S. Cannabis use
and symptoms of anxiety in adolescence and the moderating effect of the
serotonin transporter gene. Addict Biol. 2017;22(4):1081–9.
12. Duperrouzel J, Hawes SW, Lopez-Quintero C, Pacheco-Colon I, Comer J,
Gonzalez R. The association between adolescent cannabis use and anxiety:
a parallel process analysis. Addict Behav. 2018;78:107–13.
13. Ecker AH, Buckner JD. Cannabis-related problems and social anxiety: the
Mediational role of post-event processing. Substance Use Misuse. 2018;
53(1):36–41.
14. Kimbrel NA, Newins AR, Dedert EA, Van Voorhees EE, Elbogen EB, Naylor JC,
Ryan Wagner H, Brancu M, Workgroup VAM-AM, Beckham JC et al: Cannabis
use disorder and suicide attempts in Iraq/Afghanistan-era veterans. J
Psychiatr Res 2017, 89:1–5.
15. Waterreus A, Di Prinzio P, Badcock JC, Martin-Iverson M, Jablensky A,
Morgan VA. Is cannabis a risk factor for suicide attempts in men and
women with psychotic illness? Psychopharmacology. 2018;235(8):2275–85.
16. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis.
BMJ. 2006;332(7534):172–5.
17. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence
and psychotic symptoms in young people. Psychol Med. 2003;33(1):15–21.
18. Gage SH, Hickman M, Zammit S. Association between Cannabis and
psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549–56.
19. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the
association between the level of Cannabis use and risk of psychosis.
Schizophr Bull. 2016;42(5):1262–9.
20. Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthoj C. Association between
alcohol, cannabis, and other illicit substance abuse and risk of developing
schizophrenia: a nationwide population based register study. Psychol Med.
2017;47(9):1668–77.
21. Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L,
Roncero C. Cannabis consumption and psychosis or schizophrenia
development. Int J Social Psychiatry. 2018;64(7):690–704.
22. Starzer MSK, Nordentoft M, Hjorthoj C. Rates and predictors of conversion
to schizophrenia or bipolar disorder following substance-induced psychosis.
Am J Psychiatry. 2018;175(4):343–50.
23. Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, Smith DJ, Pell
JP, Sattar N, Pare G, et al. Cannabis use and risk of schizophrenia: a
Mendelian randomization study. Mol Psychiatry. 2018;23(5):1287–92.
24. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug
use: testing the cannabis gateway hypothesis. Addiction. 2006;101(4):556–69.
25. Substance Abuse and Mental Health Services Administration: About Us
[https://www.samhsa.gov/about-us]. Accessed 20 Aug 2020.
26. National Institute of Drug Abuse: 2016-2020 Strategic Plan [https://www.
drugabuse.gov/about-nida/strategic-plan/nidas-mission]. Accessed 20 Aug 2020.
27. McCantz-Katz E: 2017 Annual report snippets, NSDUH, SAMHSA, USA DHHS
- selected streamlined trends. In. Edited by Substance Abuse and Mental
Health Services Administration US Department of Health and Human
Services, vol. 1. Rockville, Maryland: SAMHSA, DHHS, USA; 2018: 1–78.
28. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of
marijuana use. N Engl J Med. 2014;370(23):2219–27.
29. Volkow ND, Hampson AJ, Baler RD. Don't worry, be happy:
Endocannabinoids and Cannabis at the intersection of stress and reward.
Annu Rev Pharmacol Toxicol. 2017;57:285–308.
30. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R,
Bloomfield MA, Curran HV, Baler R. Effects of Cannabis use on human
behavior, including cognition, motivation, and psychosis: a review. JAMA
Psychiatry. 2016;73(3):292–7.
31. Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Delta9-
tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369–77.
32. Compton WM, Volkow ND, Lopez MF. Medical marijuana Laws and Cannabis
use: intersections of health and policy. JAMA Psychiatry. 2017;74(6):559–60.
33. Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported medical
and nonmedical Cannabis use among pregnant women in the United
States. JAMA. 2019;322(2):167–9.
34. Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis
use and implications for policy: findings from the Christchurch health and
development study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317–26.
35. van Ours JC, Williams J, Fergusson D, Horwood LJ. Cannabis use and
suicidal ideation. J Health Econ. 2013;32(3):524–37.
36. Marie D, Fergusson DM, Boden JM. Links between ethnic identification,
cannabis use and dependence, and life outcomes in a New Zealand birth
cohort. Australian New Zealand J Psychiatry. 2008;42(9):780–8.
37. Fergusson DM, Boden JM. Cannabis use and adult ADHD symptoms. Drug
Alcohol Depend. 2008;95(1–2):90–6.
38. Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and
psychosocial adjustment in adolescence and young adulthood. Addiction.
2002;97(9):1123–35.
39. Reece AS, Hulse GK. Cannabis consumption patterns parallel the east-west
gradient in Canadian neural tube defect incidence: an ecological study.
Global Pediatric Health. 2019; In Press.
40. Reece AS. Chronic toxicology of cannabis. Clin Toxicol. 2009;47(6):517–24.
41. 2014–2016 NSDUH Substate Region Shapefile [https://www.samhsa.gov/
data/report/2014-2016-nsduh-substate-region-shapefile]. Accessed 20 Aug
2020.
Reece and Hulse BMC Public Health         (2020) 20:1655 Page 13 of 15
42. 2010–2012 NSDUH Substate Region Shapefile [https://www.samhsa.gov/
data/report/2010-2012-nsduh-substate-region-shapefile-zip-file-download].
Accessed 20 Aug 2020.
43. Hedden S, Gfroerer J, Barker P, Smith S, Pemberton MR, Saavedra LM,
Forman-Hoffman VL, Ringeisen H, Novak SP: Comparison of NSDUH Mental
Health Data and Methods with Other Data Sources. In: CBHSQ Data Review.
edn. Rockville (MD); 2012: 1–19.
44. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes
in Cannabis potency over the last 2 decades (1995-2014): analysis of current
data in the United States. Biol Psychiatry. 2016;79(7):613–9.
45. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd. Potency
trends of delta9-THC and other cannabinoids in confiscated marijuana from
1980-1997. J Forensic Sci. 2000;45(1):24–30.
46. Tobler W. A Computer Movie Simulating Urban Growth in the Detroit
Region. Economic Geography. 1970;46(Supplement):234–40.
47. Kapoor M, Kelejian HH, Prucha IR. Panel data models with spatially
correlated error components. J Econ. 2007;140(1):97–130.
48. VanderWeele TJ, Ding P. Sensitivity analysis in observational research:
introducing the E-value. Ann Intern Med. 2017;167(4):268–74.
49. VanderWeele TJ, Mathur MB. Commentary: developing best-practice
guidelines for the reporting of E-values. Int J Epidemiol. 2020. https://doi.
org/10.1093/ije/dyaa094.
50. VanderWeele TJ, Martin JN, Mathur MB: E-values and incidence density
sampling. Epidemiology 2020.31(6):e51–e52. https://doi.org/10.1097/ede.
0000000000001238.
51. VanderWeele TJ, Ding P. Sensitivity analysis in observational research:
introducing the E-value. Ann Intern Med. 2017;167(4):268-74. https://doi.org/
10.7326/m16-2607.
52. VanderWeele TJ, Ding P, Mathur M. Technical considerations in the use of
the E-value. J Causal Inference. 2019;7(2):1–11.
53. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for
computing E-values. Epidemiology. 2018;29(5):e45–7.
54. National Survey of Drug Use and Health 2018, NSDUH [https://www.samhsa.
gov/data/all-reports]. Accessed 20 Aug 2020.
55. Hill AB. The environment and disease: association or causation? Proc R Soc
Med. 1965;58:295–300.
56. Murphy SK, Itchon-Ramos N, Visco Z, Huang Z, Grenier C, Schrott R, Acharya
K, Boudreau MH, Price TM, Raburn DJ, Corcoran DL, Lucas JE, Mitchell JT,
McClernon FJ, Cauley M, Hall BJ, Levin ED, Kollins SH. Cannabinoid exposure
and altered DNA methylation in rat and human sperm. Epigenetics. 2018;
13(12):1208–21. https://doi.org/10.1080/15592294.2018.1554521.
57. DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, Dow-Edwards
D, Hurd YL. Maternal cannabis use alters ventral striatal dopamine D2 gene
regulation in the offspring. Biol Psychiatry. 2011;70(8):763–9.
58. Szutorisz H, DiNieri JA, Sweet E, Egervari G, Michaelides M, Carter JM, Ren Y,
Miller ML, Blitzer RD, Hurd YL. Parental THC exposure leads to compulsive
heroin-seeking and altered striatal synaptic plasticity in the subsequent
generation. Neuropsychopharmacol. 2014;39(6):1315–23.
59. Watson CT, Szutorisz H, Garg P, Martin Q, Landry JA, Sharp AJ, Hurd YL.
Genome-wide DNA methylation profiling reveals epigenetic changes in
the rat nucleus Accumbens associated with cross-generational effects of
adolescent THC exposure. Neuropsychopharmacol. 2015;40(13):2993–
3005.
60. Schrott R, Acharya K, Itchon-Ramos N, Hawkey AB, Pippen E, Mitchell JT,
Kollins SH, Levin ED, Murphy SK. Cannabis use is associated with potentially
heritable widespread changes in autism candidate gene DLGAP2 DNA
methylation in sperm. Epigenetics. 2020;15(1-2):161–73. https://doi.org/10.
1080/15592294.2019.1656158.
61. Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ. Opiates inhibit
neurogenesis in the adult rat hippocampus. Proc Natl Acad Sci U S A. 2000;
97(13):7579–84.
62. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A,
Schwartz S, Albasset S, McManus RM, Tejera D, et al. NLRP3 inflammasome
activation drives tau pathology. Nature. 2019;575(7784):669–73.
63. Cutando L., Maldonado R., Ozaita A.: Microglial Activation and Cannabis
Exposure. In: Handbook of Cannabis and Related Pathologies: Biology,
Pharmacology, Diagnosis and Treatment. Volume 1, edn. Edited by Preedy
V. New York: Academic Press; 2017: 401–412.
64. Reece AS, Norman A, Hulse GK. Cannabis exposure as an interactive
cardiovascular risk factor and accelerant of organismal ageing: a
longitudinal study. BMJ Open. 2016;6(11):e011891.
65. Wang J, Yuan W, Li MD. Genes and pathways co-associated with the
exposure to multiple drugs of abuse, including alcohol, amphetamine/
methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review
of proteomics analyses. Mol Neurobiol. 2011;44(3):269–86.
66. Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations
commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):
498–509.
67. Anderson GR, Aoto J, Tabuchi K, Foldy C, Covy J, Yee AX, Wu D, Lee SJ,
Chen L. Malenka RC et al: beta-Neurexins control neural circuits by
regulating synaptic Endocannabinoid signaling. Cell. 2015;162(3):593–606.
68. Wang H. Endocannabinoid Mediates Excitatory Synaptic Function of β-
Neurexins. Commentary: β-Neurexins Control Neural Circuits by Regulating
Synaptic Endocannabinoid Signaling. Front Neurosci. 2016;10:203.
69. Zalesky A, Solowij N, Yucel M, Lubman DI, Takagi M, Harding IH, Lorenzetti
V, Wang R, Searle K, Pantelis C, et al. Effect of long-term cannabis use on
axonal fibre connectivity. Brain. 2012;135(Pt 7):2245–55.
70. Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, Keimpema
E, Botting CH, Reinecke K, Herdegen T, et al. Miswiring the brain: Delta9-
tetrahydrocannabinol disrupts cortical development by inducing an SCG10/
stathmin-2 degradation pathway. EMBO J. 2014;33(7):668–85.
71. Reece AS, Hulse GK. Chromothripsis and epigenomics complete causality
criteria for cannabis- and addiction-connected carcinogenicity, congenital
toxicity and heritable genotoxicity. Mutat Res. 2016;789:15–25.
72. Tahir SK, Zimmerman AM. Influence of marihuana on cellular structures and
biochemical activities. Pharmacol Biochem Behav. 1991;40(3):617–23.
73. Zimmerman AM, Raj AY. Influence of cannabinoids on somatic cells in vivo.
Pharmacology. 1980;21(4):277–87.
74. Alpar A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J,
Cameron GA, Hanics J, Morris CV, Fuzik J, et al. Endocannabinoids modulate
cortical development by configuring Slit2/Robo1 signalling. Nat Commun.
2014;5:4421.
75. Cardenas A, Villalba A, de Juan RC, Pico E, Kyrousi C, Tzika AC, Tessier-
Lavigne M, Ma L, Drukker M, Cappello S, et al. Evolution of cortical
neurogenesis in amniotes controlled by Robo signaling levels. Cell. 2018;
174(3):590–606 e521.
76. Yeh ML, Gonda Y, Mommersteeg MT, Barber M, Ypsilanti AR, Hanashima C,
Parnavelas JG, Andrews WD. Robo1 modulates proliferation and
neurogenesis in the developing neocortex. J Neurosci. 2014;34(16):5717–31.
77. Russo C, Ferk F, Misik M, Ropek N, Nersesyan A, Mejri D, Holzmann K,
Lavorgna M, Isidori M, Knasmuller S. Low doses of widely consumed
cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and
chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):
179–88. https://doi.org/10.1007/s00204-018-2322-9.
78. Zimmerman AM, Zimmerman S., Raj A.Y.: Effects of Cannabinoids on
spermatogenesis in mice. In: Marihuana and medicine. edn. Edited by
Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Totowa, N. J, USA.: Humana
Press; 1999: 347–358.
79. Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M. Epigenetic regulation of
immunological alterations following prenatal exposure to marijuana
cannabinoids and its long term consequences in offspring. J NeuroImmune
Pharmacol. 2015;10(2):245–54.
80. Hwang YS, Kim YJ, Kim MO, Kang M, Oh SW, Nho YH, Park SH, Lee J.
Cannabidiol upregulates melanogenesis through CB1 dependent pathway
by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017;273:
107–14.
81. Shoyama Y, Sugawa C, Tanaka H, Morimoto S. Cannabinoids act as necrosis-
inducing factors in Cannabis sativa. Plant Signal Behav. 2008;3(12):1111–2.
82. Hughes V. Epigenetics: the sins of the father. Nature. 2014;507(7490):22–4.
83. Reece AS, Hulse GK. Epidemiological associations of various substances and
multiple cannabinoids with autism in USA. Clinical Pediatrics: Open Access.
2019;4(2):1–20.
84. Reece AS, Hulse GK. Effect of Cannabis legalization on US autism incidence
and medium term projections. Clinical Pediatrics: Open Access. 2019;4(2):1–17.
85. Reece AS, Hulse GK. Gastroschisis and autism-dual canaries in the
Californian coalmine. JAMA Surg. 2019;154(4):366–7.
86. Reece AS, Hulse GK: Impacts of Cannabinoid Epigenetics on Human
Development: Reflections on Murphy et. al. 'Cannabinoid Exposure and
Altered DNA Methylation in Rat and Human Sperm' Epigenetics 2018; 13:
1208-1221. Epigenetics 2019:1–16.
87. Brents L.: Correlates and consequences of Prenatal Cannabis Exposure (PCE):
Identifying and Characterizing Vulnerable Maternal Populations and
Reece and Hulse BMC Public Health         (2020) 20:1655 Page 14 of 15
Determining Outcomes in Exposed Offspring In: Handbook of Cannabis and
Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment.
Volume 1, edn. Edited by Preedy V.R. London: Academic Press; 2017: 160–
170.
88. Casey BJ, Cohen JD, Jezzard P, Turner R, Noll DC, Trainor RJ, Giedd J, Kaysen
D, Hertz-Pannier L, Rapoport JL. Activation of prefrontal cortex in children
during a nonspatial working memory task with functional MRI. Neuroimage.
1995;2(3):221–9.
89. Tervo-Clemmens B, Simmonds D, Calabro FJ, Day NL, Richardson GA, Luna
B. Adolescent cannabis use and brain systems supporting adult working
memory encoding, maintenance, and retrieval. Neuroimage. 2018;169:496–509.
90. Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C, Fried PA.
Prenatal marijuana exposure impacts executive functioning into young
adulthood: an fMRI study. Neurotoxicol Teratol. 2016;58:53–9.
91. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana
on visuospatial working memory: an fMRI study in young adults.
Psychopharmacology. 2010;210(3):429–38.
92. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on
visuospatial working memory: an fMRI study in young adults. Neurotoxicol
Teratol. 2006;28(2):286–95.
93. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on
response inhibition: an fMRI study of young adults. Neurotoxicol Teratol.
2004;26(4):533–42.
94. Smith A, Fried P, Hogan M, Cameron I. The effects of prenatal and current
marijuana exposure on response inhibition: a functional magnetic
resonance imaging study. Brain Cogn. 2004;54(2):147–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Reece and Hulse BMC Public Health         (2020) 20:1655 Page 15 of 15
